Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZB32 in Vitreomacular Traction
NCT07910630Phase 2Recruiting
- Sponsor
- Jingze Biotech
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JZB32 in vitreomacular traction (VMT) (2 arms), sponsored by Jingze Biotech. Primary endpoint: Percentage of study eyes with resolution of vitreomacular traction (VMT) assessed by OCT at 28 days. Started Sep 2026; status: recruiting.
02
Drugs
JZB32
03
Conditions
vitreomacular traction (VMT)
Beyond the preview
Go deeper on NCT07910630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07910630.